lobbying_filings_raw: 657b474a-e0aa-40a8-823f-aaff4fcda13e
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | amount_reported | is_amendment | is_no_activity | is_termination | raw_json | registrant_state | registrant_country | registrant_house_id | client_state | client_ppb_state | client_country | client_ppb_country | client_general_description | client_government_entity | affiliated_org_count | client_entity_id | client_government_unit_id | client_match_method | client_match_confidence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 657b474a-e0aa-40a8-823f-aaff4fcda13e | Q3 | 400579747 | ENDGAME STRATEGIES, LLC | 193065 | ASSOCIATION OF ACCESSIBLE MEDICINES | 2021 | third_quarter | 2021-10-18T17:01:47.537000-04:00 | 30000.0 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/657b474a-e0aa-40a8-823f-aaff4fcda13e/", "filing_uuid": "657b474a-e0aa-40a8-823f-aaff4fcda13e", "filing_type": "Q3", "filing_type_display": "3rd Quarter - Report", "filing_year": 2021, "filing_period": "third_quarter", "filing_period_display": "3rd Quarter (July 1 - Sep 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/657b474a-e0aa-40a8-823f-aaff4fcda13e/print/", "filing_document_content_type": "text/html", "income": "30000.00", "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Steven J. Duffield", "dt_posted": "2021-10-18T17:01:47.537000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "1717 K Street, NW", "registrant_address_2": "Suite 900", "registrant_different_address": false, "registrant_city": "Washington", "registrant_state": "DC", "registrant_zip": "20006", "registrant": {"id": 400579747, "url": "https://lda.senate.gov/api/v1/registrants/400579747/", "house_registrant_id": null, "name": "ENDGAME STRATEGIES, LLC", "description": "Policy advocacy", "address_1": "1717 K Street, NW", "address_2": "Suite 900", "address_3": null, "address_4": null, "city": "Washington", "state": "DC", "state_display": "District of Columbia", "zip": "20006", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "STEVEN J. DUFFIELD", "contact_telephone": "+1 202-683-6880", "dt_updated": "2026-01-20T13:06:40.316398-05:00"}, "client": {"id": 193065, "url": "https://lda.senate.gov/api/v1/clients/193065/", "client_id": 75, "name": "ASSOCIATION OF ACCESSIBLE MEDICINES", "general_description": "Trade association working to ensure generic and biosimilar medicines are more accessible.", "client_government_entity": false, "client_self_select": null, "state": "DC", "state_display": "District of Columbia", "country": "US", "country_display": "United States of America", "ppb_state": "DC", "ppb_state_display": "District of Columbia", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2017-10-10"}, "lobbying_activities": [{"general_issue_code": "CPT", "general_issue_code_display": "Copyright/Patent/Trademark", "description": "Protection of inter partes review process to invalidate improperly granted patents", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 51331, "prefix": null, "prefix_display": null, "first_name": "STEVEN", "nickname": null, "middle_name": null, "last_name": "DUFFIELD", "suffix": null, "suffix_display": null}, "covered_position": "Chief counsel/Deputy Staff Director, Senate Republican Conference; Chief counsel/Deputy staff director, Senate Republican Policy Committee; Judiciary analyst/counsel, Senate Republican Policy Committee", "new": false}], "government_entities": [{"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} | DC | US | DC | DC | US | US | Trade association working to ensure generic and biosimilar medicines are more accessible. | 0 | 0 |